Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to -$785000.0.

  • Guided Therapeutics' Net Income towards Common Stockholders fell 1343.93% to -$785000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year decrease of 1881.36%. This contributed to the annual value of -$2.6 million for FY2024, which is 3107.21% up from last year.
  • According to the latest figures from Q3 2025, Guided Therapeutics' Net Income towards Common Stockholders is -$785000.0, which was down 1343.93% from -$856000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Net Income towards Common Stockholders ranged from a high of -$51000.0 in Q3 2021 and a low of -$1.9 million during Q4 2022
  • For the 5-year period, Guided Therapeutics' Net Income towards Common Stockholders averaged around -$827263.2, with its median value being -$758000.0 (2024).
  • Per our database at Business Quant, Guided Therapeutics' Net Income towards Common Stockholders skyrocketed by 8287.02% in 2021 and then crashed by 196666.67% in 2022.
  • Guided Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$509000.0 in 2021, then crashed by 264.83% to -$1.9 million in 2022, then soared by 74.74% to -$469000.0 in 2023, then crashed by 49.25% to -$700000.0 in 2024, then decreased by 12.14% to -$785000.0 in 2025.
  • Its Net Income towards Common Stockholders stands at -$785000.0 for Q3 2025, versus -$856000.0 for Q2 2025 and -$463000.0 for Q1 2025.